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aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the 
prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients 
receiving highly or moderately emetogenic chemotherapy (HEC/MEC). Patients & 
methods: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg 
ondansetron for up to four cycles of HEC/MEC. Results: In all on-study chemotherapy cycles, 
complete response rates were higher in patients in the 20 μg/kg palonosetron group than 
the ondansetron group. Treatment-emergent adverse events were comparable between 
the palonosetron 20 μg/kg and ondansetron groups. conclusion: Over four cycles of HEC/
MEC, 20 μg/kg palonosetron was an efficacious and safe treatment for the prevention of 
chemotherapy-induced nausea and vomiting in pediatric cancer patients.
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Chemotherapy-induced nausea and vomiting (CINV) are common and distressing side effects in 
cancer patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic 
chemotherapy (MEC) regimens [1,2]. CINV negatively impacts on patient quality of life [3], and 
can lead to medical complications and to noncompliance or premature discontinuation of anti-
cancer therapy [4]. It is recognized that children receiving chemotherapy are more prone to vomiting 
than adults, and it is estimated that 70% of pediatric cancer patients receiving chemotherapy will 
develop CINV [2].
Prevention of CINV in adult cancer patients receiving HEC or MEC regimens can be achieved 
through the use of antiemetic agents, a combination of a 5-hydroxytryptamine-3 (5-HT
3
) receptor 
antagonist, a corticosteroid and a neurokinin-1 (NK
1
) receptor antagonist is recommended [5–7]. 
While fewer studies of these agents have been performed in pediatric cancer patients than in adults, 
at the time of the study design, the combination of a 5-HT
3
 receptor antagonist with a corticosteroid 
was recommended for pediatric patients receiving HEC or MEC chemotherapy regimens [2,5,6]. 
In later guidance from the Pediatric Oncology Group of Ontario (POGO), children scheduled to 
receive HEC are recommended to receive antiemetic prophylactic therapy of ondansetron or grani-
setron plus dexamethasone and aprepitant (≥12 years of age and receiving antineoplastic drugs not 
known to interact with aprepitant) or ondansetron or granisetron plus dexamethasone (<12 years of 
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age or receiving aprepitant interacting agents) [8]. 
For patients scheduled to receive MEC, the rec-
ommendation in the POGO guidelines is that 
patients should receive ondansetron or grani-
setron plus dexamethasone. Despite prophy-
lactic use of antiemetic agents many patients, 
especially children, still experience nausea and 
vomiting [9].
Palonosetron hydrochloride (Aloxi®) is a 
comparatively new 5-HT
3
 receptor antagonist 
with a higher affinity (at least 30-fold higher) 
for the 5-HT
3
 receptor, and a longer plasma 
elimination half life compared with older class 
agents (ondansetron, granisetron and dola-
setron) [10]. Its unique interaction with the 
5-HT
3
 receptor at the molecular level, and 
its effects on the NK
1
 signaling pathway may 
offer an advantage for efficacy over older agents 
in this class [11–13]. In a large meta-analysis of 
16 randomized studies, in predominantly adult 
patients, palonosetron was reported to be more 
effective than other 5-HT
3
 antagonists for the 
prevention of CINV associated with MEC or 
HEC regimens in studies that did not allow 
dexamethasone [14]. In two small randomized 
controlled studies in pediatric cancer patients, 
intravenous palonosetron (3–10 μg/kg) was 
reported to be a well-tolerated and effective 
antiemetic treatment in patients receiving HEC 
or MEC regimens [15,16].
We have evaluated the efficacy and safety 
of two palonosetron doses (10 and 20 μg/kg) 
compared with ondansetron (3 × 150 μg/kg) 
over four cycles, for the prevention of CINV 
in 493 pediatric cancer patients scheduled to 
receive HEC or MEC [17]. The primary end 
point was complete response (CR) during the 
acute phase of the first on-study chemotherapy 
cycle. CRs were reported in 90 (54.2%) of 
166 patients treated with 10 μg/kg, 98 (59.4%) 
of 165 patients treated with 20 μg/kg palonose-
tron and 95 (58.6%) of 162 patients treated with 
ondansetron. Noninferiority compared with 
ondansetron was reported (δ = -15%) for the 
higher dose of palonosetron (97.5% CI: -11.7–
12.4; p = 0.0022). No clinically relevant differ-
ences in the safety profile of the treatments were 
found [18]. These findings led to the approval for 
the 20 μg/kg dose of palonosetron by both the 
US FDA and EMA for the prevention of CINV 
in pediatric patients aged 1 month to <17 years 
undergoing treatment with MEC or HEC [19,20]. 
Herein, we now report secondary end points 
and the safety profile of palonosetron compared 
with ondansetron across four treatment cycles 
from this pivotal study, with each cycle assessed 
independently.
Patients & methods
●● study design & patients
This was a double-blind, double-dummy ran-
domized, multinational Phase III study per-
formed at 71 sites in the USA, Latin America, 
Europe and Russia. The study design has been 
detailed previously [17]. Briefly, eligible patients 
were aged from newborn (full term; ≥37 weeks) 
to <17 years old, naive or non-naive to chemo-
therapy, scheduled to undergo MEC or HEC 
on day 1 for histologically/cytologically con-
firmed malignant disease. For patients with 
known hepatic or renal impairment or known 
history of, or predisposition to cardiac abnor-
malities, inclusion was permitted if in the 
opinion of the site investigator, the existence 
of any such condition should not have jeop-
ardized patient safety. Eastern Cooperative 
Oncology Group performance status ≤2 was 
required in patients aged ≥10 years. The main 
exclusion criteria were for patients: suffering 
from ongoing vomiting from any organic cause 
(including patients with history of gastric out-
let obstruction or intestinal obstruction due to 
adhesions or volvulus); with a history of gastric 
outlet or intestinal obstruction; who suffered 
vomiting, retching or nausea within the 24 h 
prior to study drug administration; who had 
received any drug with a potential antiemetic 
effect within the 24 h prior to treatment initia-
tion; who had received total body irradiation or 
radiotherapy of the upper abdomen, cranium, 
craniospinal regions or  pelvis within 1 week of 
study entry; with baseline prolongation of the 
QTc interval (>460 ms).
The study was conducted in accordance with 
the Declaration of Helsinki (2008) and the 
International Conference on Harmonization 
of Technical Requirements of Pharmaceuticals 
for Human Use E6 guideline. Approval was 
obtained from the appropriate institutional eth-
ics committees, institutional review boards and 
regulatory authorities prior to study initiation. 
Written informed consent was obtained from 
parent(s)/legal guardian(s) prior to enrollment. 
For patients of appropriate age and maturity, 
assent was obtained in compliance with local 
laws and regulations. The initial informed con-
sent/assent was given for the duration of four 
on-study chemotherapy cycles.
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●● Procedures
Patients were randomized to either 10 μg/kg 
palonosetron, up to a maximum dose of 0.75 mg, 
administered 30 ± 5 min before chemotherapy 
as a 15-minintravenous infusion, or to 20 μg/kg 
palonosetron, up to a maximum dose of 1.50 mg, 
administered identically to the 10 μg/kg dose, or 
to 3 × 150 μg/kg ondansetron (every 4 h), up to 
a maximum total dose of 32 mg, administered as 
a 15-minintravenous infusion 30 ± 5 min before 
chemotherapy, as well as 4 and 8 h ± 30 min after 
first administration. Study drug could be admin-
istered for up to four cycles of HEC or MEC. In 
accordance with antiemetic guidelines, patients 
also received concomitant dexamethasone, if 
deemed appropriate by the investigator, unless 
this was contraindicated or if corticosteroids 
were also included in the chemotherapy cycle. 
Dosing and administration of dexamethasone 
were in accordance with local standard clinical 
practice.
●● Outcomes
As part of a protocol specified analysis, selected 
secondary end points for each phase (acute, 
delayed and overall) of on-study chemotherapy 
cycles 2–4 were examined. These included the 
proportion of patients showing CRs, and the 
proportion of patients who did not experience 
vomiting, emetic episodes, nausea (patients aged 
≥6 years only), and who avoided antiemetic res-
cue medication. CR was defined as no vomit-
ing, retching or antiemetic rescue medication. 
Emetic episodes were defined as one or more 
continuous vomits (expulsion of stomach con-
tents through the mouth) or retches (an attempt 
to vomit that is not productive of stomach con-
tents). The acute phase was defined as 0–24 h 
after the start of chemotherapy on day 1 of each 
on-study chemotherapy cycle, the delayed and 
overall phases were defined as >24–120 h and 
0–120 h after the start of chemotherapy on day 1 
of each on-study chemotherapy cycle. These end 
points have been previously reported for cycle 1.
In the first on-study treatment cycle, a diary 
was provided to the patient or their caregivers 
for the assessment of emetic episodes during the 
acute and delayed phases. In the diary, every epi-
sode of retching and vomiting, as well as any res-
cue drug given, was to be entered [17]. Nausea was 
assessed by a yes/no question in the electronic 
case report form. In subsequent on-study chemo-
therapy cycles (2–4), a diary was not used, for 
the acute and delayed phases; nausea, vomiting 
and retching were assessed by yes/no questions 
in the electronic case report form.
Secondary efficacy analyses also included 
summary statistics by age and chemotherapy-
related emetogenicity strata.
Safety during cycles 1–4 was assessed on adverse 
events, physical examinations, vital signs, labora-
tory assessments and 12-lead electrocardiograms 
(recorded in triplicate at screening and between 
days 7 and 10 of each cycle) as detailed previ-
ously [17]. Adverse events were coded using the 
Medical Dictionary for Regulatory Activities 
(MedDRA), version 14.0. All treatment-emergent 
adverse events (TEAEs), whether nonserious, seri-
ous or adverse drug reactions, had their severity 
(mild, moderate or severe), intensity (rated accord-
ing to the descriptions and grading scales of the 
Common Terminology Criteria for Adverse Events 
[CTCAE], version 4.03) and investigator’s opinion 
on their relationship to the study drug, recorded.
●● statistical analysis
Statistical analyses for the primary outcome 
measure have been described previously in detail 
(supplementary Methods) [17]. The full analysis set 
(FAS) included all randomized patients receiv-
ing the active study drug and HEC or MEC. 
Following the intent-to-treat principle, efficacy 
in the FAS across all on-study cycles was ana-
lyzed according to treatment assignment at ran-
domization. The safety population comprised all 
patients who received at least one dose of study 
drug and had at least one safety assessment. For 
individual on-study treatment cycles, safety was 
analyzed according to actual treatment received 
in each cycle. When considering the overall study 
period (across all cycles), safety was analyzed 
according to actual  treatment received in cycle 1.
Differences in proportions were analyzed 
using the Mantel–Haenszel method on the FAS 
population at a type I error of 5%.
All statistical outputs were produced using 
SAS® Software version 9.2 or later (SAS Institute 
Inc., NC, USA). Formal testing for statistical 
significance was limited to the analysis of the 
primary end point [17].
The study is registered with ClinicalTrials.
gov, number NCT01442376.
Results
●● Patients & characteristics
Between 12 September 2011 and 26 October 
2012, 502 patients were randomly assigned 
to treatment. Eight patients did not receive 
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study drug, while 494 were treated. Most ran-
domized patients completed the first on-study 
chemotherapy cycle: 167 (98.8%) of 169, 165 
(97.6%) of 169 and 162 (98.8%) of 164 in the 
10 μg/kg palonosetron, 20 μg/kg palonosetron 
and ondansetron groups, respectively (Figure 1). 
One patient receiving chemotherapy of low eme-
togenicity was excluded from the FAS, which 
comprised 493 patients: 166 in the 10 μg/kg 
palonosetron group, 165 in the 20 μg/kg palo-
nosetron group and 162 in the ondansetron 
group. The rate of patients not continuing at 
each subsequent on-study chemotherapy cycle 
was approximately 50% across the 10 μg/kg, 
20 μg/kg palonosetron and the ondansetron 
groups with 19 (11.4%) of 166, 31 (18.8%) of 
165 and 19 (11.7%) of 162 patients completing 
all four on-study chemotherapy cycles, respec-
tively (in accordance with the protocol, patients 
could continue to participate from cycle 2 up 
to 4 but this was not mandatory; reasons for 
noncontinuation were not recorded).
Patient baseline characteristics in the FAS 
were generally comparable between the treat-
ment groups [17]. The proportion of patients 
undergoing single-day or multiple-day chemo-
therapy (regardless of emetogenicity) was broadly 
similar across treatment groups between cycles 
(supplementary table 1). The majority of patients 
were male (262 [53.1%] of 493), white (469; 
95.1%), and median age was 7.1 years (range: 
2.1 months to 16.9 years). Across the palonose-
tron (10 and 20 μg/kg) and ondansetron treat-
ment groups, the numbers of patients with pri-
mary cancers at baseline were balanced, and most 
patients received MEC regimens (112 [67.5%] of 
166, 116 [70.3%] of 165 and 111 [68.5%] of 
162 patients, respectively). The most frequently 
administered chemotherapeutic agents during 
the overall study period were vinca alkaloids and 
analogues (105 [63.3%] of 166, 107 [64.8%] 
of 165 and 111 [68.5%] of 162 patients), and 
nitrogen mustard analogues (96 [57.8%], 104 
[63.0%] and 106 [65.4%] patients, respectively).
●● efficacy
As previously reported [17], in the acute phase 
of the first on-study chemotherapy cycle, non-
inferiority versus ondansetron was shown for 
20 μg/kg palonosetron (ΔCR: 0.36% [97.5% CI: 
-11.7–12.4]; p = 0.0022). Noninferiority versus 
ondansetron was not demonstrated for 10 μg/kg 
palonosetron in the acute phase (ΔCR: -4.41% 
[97.5% CI: -16.4–7.6]).
Extending this analysis, we found that in all 
on-study chemotherapy cycles, and all phases, 
the CR rates were higher in patients treated in 
the palonosetron 20 μg/kg group compared 
with those treated with ondansetron (table 1 & 
Figure 2). Additionally, Mantel–Haenszel analy-
sis of data from the acute phase of the second 
on-study chemotherapy cycle (ΔCR: 5.79% 
[95% CI: -9.0–20.6%]) was consistent with the 
demonstration in the acute phase of the first on-
study chemotherapy cycle of the noninferiority 
of 20 μg/kg palonosetron compared with ondan-
setron. Similar Mantel–Haenszel analyses could 
not be performed for on-study chemotherapy 
cycles 3 and 4 due to the low number of patients. 
A post hoc analysis of CR rates in patients who 
only received scheduled chemotherapy (regard-
less of the emetogenicity) on day 1 of the first on-
study chemotherapy cycle confirmed higher rates 
in the palonosetron 20 μg/kg group compared 
with those treated with ondansetron in both the 
acute and delayed phases (supplementary table 2). 
The number of patients in this subgroup was 
too small to draw definitive conclusions beyond 
cycle 1. A summary of CR rates and the propor-
tion of patients without emetic episodes accord-
ing to whether patients received HEC or MEC, 
dexamethasone or no dexamethasone, single or 
multiday chemotherapy and the timing of HEC/
MEC administration across on-study treatment 
cycles 1–4 is shown in supplementary table 3. The 
mean dexamethasone doses received in the acute 
and delayed phases of each cycle is shown in 
supplementary table 4.
During all phases of on-study chemotherapy 
cycles 1–4, the proportion of patients who had 
no vomiting was higher for patients treated in 
the 20 μg/kg palonosetron group compared with 
those in the ondansetron group; differences 
being mostly ≥10% higher in the 20 μg/kg palo-
nosetron than the ondansetron group (table 1). 
Similarly, in the 20 μg/kg palonosetron treat-
ment group the proportion of patients without 
emetic episodes was higher than in the ondan-
setron group during all phases of all on-study 
chemotherapy cycles. The proportion of patients 
who avoided antiemetic rescue medication was 
also higher in the 20 μg/kg palonosetron group 
compared with the ondansetron group except 
for during the acute phase of the first and second 
on-study chemotherapy cycles (table 1).
As prespecified, the incidence of nausea was 
investigated only in patients aged ≥6 years (table 1). 
The proportion of patients who experienced no 
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Figure 1. study profile by treatment cycle†. 
†In patients randomly assigned to the study treatment group according to the randomized treatment. 
‡Includes one patient who received low emetogenic chemotherapy, this patient was excluded from the full analysis set.
502 patients were enrolled and
 randomly assigned
169 to 10 µg/kg
palonosetron
169 to 20 µg/kg
palonosetron
164 to 3 × 150 µg/kg
ondansetron
2 patients were
not treated
4 patients were
not treated
2 patients were
not treated
167 (99%) randomly
assigned treated
patients‡
165 (98%) randomly
assigned treated patients
162 (99%) randomly
assigned treated patients
166 (98%) 
completed cycle 1
163 (96%) 
completed cycle 1
160 (98%) 
completed cycle 1
84 (50%) 
completed cycle 2
89 (53%) 
completed cycle 2
86 (52%) 
completed cycle 2
43 (25%) 
completed cycle 3
59 (35%) 
completed cycle 3
44 (27%) 
completed cycle 3
19 (11%) 
completed cycle 4
31 (18%) 
completed cycle 4
19 (12%) 
completed cycle 4
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nausea was higher in the 20 μg/kg palonosetron 
compared with the ondansetron group except for 
during the delayed phase of the fourth on-study 
chemotherapy cycle.
●● safety
The safety population comprised 494 patients: 
167 were treated with 10 μg/kg palonosetron 
(including one patient who received low emeto-
genicity and one randomly assigned to the 
20 μg/kg palonosetron group), 163 patients 
received 20 μg/kg palonosetron and 164 were 
treated with ondansetron (including one patient 
randomly assigned to 10 μg/kg palonosetron 
and one to the 20 μg/kg palonosetron group). 
A summary of overall TEAEs (reported through 
all four on-study chemotherapy cycles) and 
those occurring at each treatment cycle is shown 
in table 2. The proportion of patients reporting 
at least one TEAE overall was lower in those 
receiving 20 μg/kg palonosetron (130 [79.8%] 
of 163) than 10 μg/kg palonosetron (143 
[85.6%] of 167) or ondansetron (145 [88.4%] of 
164); this trend was apparent at each treatment 
cycle. The most commonly reported TEAEs 
(≥5%) were those coded by preferred terms 
under MedDRA System Organ Class (SOC) of 
blood and lymphatic disorders, gastrointestinal 
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table 1. Patients with complete response, without vomiting, emetic episode, antiemetic rescue 
medication or nausea, by on-study chemotherapy cycle.
Parameter/cycle/phase Palonosetron (10 μg/kg) Palonosetron  
(20 μg/kg)
Ondansetron  
(3 × 150 μg/kg)
CR      
Cycle 1, N 166 165 162
Acute 90 (54.2; 46.3–61.9) 98 (59.4; 51.5–66.9) 95 (58.6; 50.6–66.2)
Delayed 48 (28.9; 22.3–36.5) 64 (38.8; 31.4–46.7) 46 (28.4; 21.7–36.1)
Overall 39 (23.5; 17.4–30.8) 54 (32.7; 25.8–40.5) 39 (24.1; 17.9–31.5)
Cycle 2, N 81 90 86
Acute 54 (66.7; 55.2–76.5) 59 (65.6; 54.7–75.1) 51 (59.3; 48.2–69.6)
Delayed 29 (35.8; 25.7–47.3) 35 (38.9; 29.0–49.8) 28 (32.6; 23.1–43.6)
Overall 27 (33.3; 23.5–44.8) 32 (35.6; 25.9–46.4) 25 (29.1; 20.0–40.0)
Cycle 3, N 43 59 44
Acute 19 (44.2; 29.4–60.0) 48 (81.4; 68.7–89.9) 28 (63.6; 47.7–77.2)
Delayed 13 (30.2; 17.7–46.3) 25 (42.4; 29.8–55.9) 12 (27.3; 15.5–43.0)
Overall 12 (27.9; 15.8–43.9) 24 (40.7; 28.3–54.2) 12 (27.3; 15.5–43.0)
Cycle 4, N 19 31 19
Acute 9 (47.4; 25.2–70.5) 20 (64.5; 45.4–80.2) 10 (52.6; 29.5–74.8)
Delayed 6 (31.6; 13.6–56.5) 10 (32.3; 17.3–51.5) 5 (26.3; 10.1–51.4)
Overall 4 (21.1; 7.0–46.1) 9 (29.0; 14.9–48.2) 4 (21.1; 7.0–46.1)
No vomiting      
Cycle 1, N 166 165 162
Acute 133 (80.1; 73.1–85.7) 138 (83.6; 76.9–88.8) 119 (73.5; 65.8–79.9)
Delayed 113 (68.1; 60.3–75.0) 122 (73.9; 66.4–80.3) 94 (58.0; 50.0–65.6)
Overall 98 (59.0; 51.1–66.5) 114 (69.1; 61.4–75.9) 83 (51.2; 43.3–59.1)
Cycle 2, N 81 90 86
Acute 69 (85.2; 75.2–91.8) 79 (87.8; 78.8–93.4) 66 (76.7; 66.2–84.9)
Delayed 66 (81.5; 71.0–88.9) 75 (83.3; 73.7–90.1) 65 (75.6; 64.9–83.9)
Overall 59 (72.8; 61.6–81.9) 70 (77.8; 67.5–85.6) 54 (62.8; 51.6–72.8)
Cycle 3, N 43 59 44
Acute 33 (76.7; 61.0–87.7) 56 (94.9; 84.9–98.7) 36 (81.8; 66.8–91.3)
Delayed 35 (81.4; 66.1–91.1) 52 (88.1; 76.5–94.7) 31 (70.5; 54.6–82.8)
Overall 29 (67.4; 51.3–80.5) 52 (88.1; 76.5–94.7) 28 (63.6; 47.7–77.2)
Cycle 4, N 19 31 19
Acute 15 (78.9; 53.9–93.0) 27 (87.1; 69.2–95.8) 13 (68.4; 43.5–86.4)
Delayed 15 (78.9; 53.9–93.0) 27 (87.1; 69.2–95.8) 14 (73.7; 48.6–89.9)
Overall 14 (73.7; 48.6–89.9) 25 (80.6; 61.9–91.9) 10 (52.6; 29.5–74.8)
No emetic episode      
Cycle 1, N 166 165 162
Acute 122 (73.5; 66.0–79.9) 132 (80.0; 72.9–85.7) 111 (68.5; 60.7–75.5)
Delayed 102 (61.4; 53.6–68.8) 113 (68.5; 60.7–75.4) 86 (53.1; 45.1–60.9)
Overall 87 (52.4; 44.5–60.2) 105 (63.6; 55.8–70.9) 74 (45.7; 37.9–53.7)
Cycle 2, N 81 90 86
Acute 67 (82.7; 72.4–89.9) 79 (87.8; 78.8–93.4) 64 (74.4; 63.7–82.9)
Delayed 66 (81.5; 71.0–88.9) 72 (80.0; 70.0–87.4) 63 (73.3; 62.4–82.0)
Overall 58 (71.6; 60.3–80.8) 69 (76.7; 66.3–84.7) 52 (60.5; 49.3–70.7)
Data presented are number of patients (% of the full analysis set in each cycle; Wilson 95% CI).
CR: Complete response.
disorders, general disorders and administra-
tion site conditions, investigations and nerv-
ous system disorders (table 3). Twenty-seven 
patients experienced TEAEs considered to be 
related to study drug; these occurred in on-study 
chemotherapy cycles 1 and 2, and were evenly 
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distributed across the treatment groups (table 2; 
supplementary table 5). The most frequently 
reported drug-related TEAE was headache, in 
eight patients; four treated with 10 μg/kg palon-
osetron, one treated with 20 μg/kg palonosetron 
and three treated with ondansetron (table 4). 
Parameter/cycle/phase Palonosetron (10 μg/kg) Palonosetron  
(20 μg/kg)
Ondansetron  
(3 × 150 μg/kg)
No emetic episode      
Cycle 3, N 43 59 44
Acute 32 (74.4; 58.5–86.0) 56 (94.9; 84.9–98.7) 35 (79.5; 64.2–89.7)
Delayed 35 (81.4; 66.1–91.1) 50 (84.7; 72.5–92.4) 30 (68.2; 52.3–80.9)
Overall 28 (65.1; 49.0–78.5) 50 (84.7; 72.5–92.4) 27 (61.4; 45.5–75.3)
Cycle 4, N 19 31 19
Acute 15 (78.9; 53.9–93.0) 27 (87.1; 69.2–95.8) 13 (68.4; 43.5–86.4)
Delayed 15 (78.9; 53.9–93.0) 26 (83.9; 65.5–93.9) 12 (63.2; 38.6–82.8)
Overall 14 (73.7; 48.6–89.9) 24 (77.4; 58.5–89.7) 9 (47.4; 25.2–70.5)
No antiemetic rescue medication 
Cycle 1, N 166 165 162
Acute 115 (69.3; 61.6–76.1) 124 (75.2; 67.7–81.4) 123 (75.9; 68.5–82.1)
Delayed 64 (38.6; 31.2–46.4) 75 (45.5; 37.8–53.4) 57 (35.2; 28.0–43.1)
Overall 60 (36.1; 28.9–44.0) 69 (41.8; 34.3–49.8) 54 (33.3; 26.2–41.2)
Cycle 2, N 81 90 86
Acute 58 (71.6; 60.3–80.6) 63 (70.0; 59.3–79.0) 62 (72.1; 61.2–81.0)
Delayed 33 (40.7; 30.1–52.2) 40 (44.4; 34.1–55.3) 31 (36.0; 26.2–47.2)
Overall 32 (39.5; 29.0–51.0) 36 (40.0; 30.0–50.9) 28 (32.6; 23.1–43.6)
Cycle 3, N 43 59 44
Acute 23 (53.5; 37.8–68.5) 50 (84.7; 72.5–92.4) 32 (72.7; 57.0–84.5)
Delayed 14 (32.6; 19.5–48.7) 29 (49.2; 36.1–62.4) 13 (29.5; 17.2–45.4)
Overall 14 (32.6; 19.5–48.7) 28 (47.5; 34.5–60.8) 13 (29.5; 17.2–45.4)
Cycle 4, N 19 31 19
Acute 10 (52.6; 29.5–74.8) 23 (74.2; 55.1–87.5) 10 (52.6; 29.5–74.8)
Delayed 6 (31.6; 13.6–56.5) 10 (32.3; 17.3–51.5) 5 (26.3; 10.1–51.4)
Overall 5 (26.3; 10.1–51.4) 10 (32.3; 17.3–51.5) 4 (21.1; 7.0–46.1)
No nausea      
Cycle 1, N 97 96 93
Acute 63 (64.9; 54.5–74.2) 69 (71.9; 61.6–80.3) 62 (66.7; 56.0–75.9)
Delayed 55 (56.7; 46.3–66.6) 63 (65.6; 55.2–74.8) 47 (50.5; 40.0–61.0)
Overall 46 (47.4; 37.3–57.8) 56 (58.3; 47.8–68.2) 40 (43.0; 32.9–53.7)
Cycle 2, N 44 56 45
Acute 32 (72.7; 57.0–84.5) 45 (80.4; 67.2–89.3) 33 (73.3; 57.8–84.9)
Delayed 29 (65.9; 50.0–79.1) 43 (76.8; 63.3–86.6) 32 (71.1; 55.5–83.2)
Overall 25 (56.8; 41.1–71.3) 40 (71.4; 57.6–82.3) 25 (55.6; 40.1–70.0)
Cycle 3, N 23 37 24
Acute 19 (82.6; 60.5–94.3) 35 (94.6; 80.5–99.1) 17 (70.8; 48.8–86.6)
Delayed 20 (87.0; 65.3–96.6) 31 (83.8; 67.3–93.2) 17 (70.8; 48.8–86.6)
Overall 17 (73.9; 51.3–88.9) 30 (81.1; 64.3–91.4) 15 (62.5; 40.8–80.5)
Cycle 4, N 9 22 10
Acute 5 (55.6; 22.7–84.7) 19 (86.4; 64.0–96.4) 7 (70.0; 35.4–91.9)
Delayed 7 (77.8; 40.2–96.1) 17 (77.3; 54.2–91.3) 9 (90.0; 54.1–99.5)
Overall 5 (55.6; 22.7–84.7) 16 (72.7; 49.6–88.4) 7 (70.0; 35.4–91.9)
Data presented are number of patients (% of the full analysis set in each cycle; Wilson 95% CI).
CR: Complete response.
table 1. Patients with complete response, without vomiting, emetic episode, antiemetic rescue 
medication or nausea, by on-study chemotherapy cycle (cont.).
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Figure 2. complete response rates in pediatric patients treated with 10 or 20 μg/kg palonosetron 
or ondansetron during the acute phase (a), delayed phase (B) and overall phases (c) of four  
on-study chemotherapy cycles.
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Treatment-related cardiac disorders were lim-
ited to the first on-study chemotherapy cycle in 
one patient treated with 10 μg/kg palonosetron 
(sinus tachycardia and conduction disorder) and 
two treated with ondansetron (one with sinus 
tachycardia and conduction disorder, and one 
with sinus tachycardia). Treatment-related pro-
longed electrocardiogram QT was reported in 
one patient treated with 20 μg/kg palonosetron 
(on-study chemotherapy cycles 1 and 2) and two 
patients with ondansetron (one in both on-study 
chemotherapy cycles 1 and 2, and the other in 
cycle 1).
The number of patients with CTCAE grade 
≥3 TEAEs was lower in the 10 μg/kg palonose-
tron than ondansetron treatment group across 
on-study chemotherapy cycles 1–4, with the 
exception of cycle 3. For the 20 μg/kg palonose-
tron group compared with the ondansetron treat-
ment group, this effect was more pronounced, 
with incidences of grade ≥3 TEAEs more than 
10% lower across each of the four on-study 
chemotherapy cycles (table 2). Only five TEAEs 
were considered to be study treatment related. 
These included three patients receiving 20 μg/kg 
palonosetron, one in cycle 1 (grade 3 infusion 
site pain) and two in cycle 2 (one with grade 
3 electrocardiogram QT prolongation and one 
with grade 4 diarrhea and grade 3 dehydration), 
and two patients in on-study chemotherapy cycle 
2, one receiving 10 μg/kg palonosetron (grade 3 
thrombocytopenia) and one receiving ondanse-
tron (grade 3 hypertension). The distribution of 
serious adverse events was also similar between 
the treatment groups, and across the on-study 
chemotherapy cycles and was considered to 
be drug related only in one patient receiving 
20 μg/kg palonosetron in on-study chemotherapy 
cycle 2 (grade 4 diarrhea and grade 3 dehydra-
tion). TEAEs leading to study withdrawal were 
table 2. summary of overall treatment-emergent adverse events and serious adverse events by 
on-study chemotherapy cycle.
category N Palonosetron 
(10 μg/kg)
N Palonosetron 
(20 μg/kg)
N Ondansetron (3 × 
150 μg/kg)
At least one TEAE
Overall 167 143 (85.6) 163 130 (79.8) 164 145 (88.4)
Cycle 1 167 134 (80.2) 163 113 (69.3) 164 134 (81.7)
Cycle 2 84 64 (76.2) 90 58 (64.4) 86 71 (82.6)
Cycle 3 43 31 (72.1) 59 33 (55.9) 44 30 (68.2)
Cycle 4 20 15 (75.0) 31 15 (48.4) 18 13 (72.2)
At least one drug-related TEAE 
Overall 167 9 (5.4) 163 8 (4.9) 164 10 (6.1)
Cycle 1 167 7 (4.2) 163 7 (4.3) 164 7 (4.3)
Cycle 2 84 3 (3.6) 90 2 (2.2) 86 4 (4.7)
Cycle 3 43 0 59 0 44 0
Cycle 4 20 0 31 0 18 0
At least one SAE 
Overall 167 68 (40.7) 163 62 (38.0) 164 70 (42.7)
Cycle 1 167 52 (31.1) 163 43 (26.4) 164 55 (33.5)
Cycle 2 84 28 (33.3) 90 20 (22.2) 86 25 (29.1)
Cycle 3 43 11 (25.6) 59 11 (18.6) 44 10 (22.7)
Cycle 4 20 6 (30.0) 31 8 (25.8) 18 7 (38.9)
At least one TEAE > grade 3 
Overall 167 111 (66.5) 163 108 (66.3) 164 124 (75.6)
Cycle 1 167 93 (55.7) 163 86 (52.8) 164 108 (65.9)
Cycle 2 84 50 (59.5) 90 42 (46.7) 86 56 (65.1)
Cycle 3 43 27 (62.8) 59 25 (42.4) 44 25 (56.8)
Cycle 4 20 12 (60.0) 31 12 (38.7) 18 11 (61.1)
Data are number of patients (%) in the safety population. Percentage values are based on the number of patients (N) in each cycle 
in each treatment group.
SAE: Serious adverse event; TEAE: Treatment-emergent adverse event.
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reported in three patients, all were serious adverse 
events but were not considered to be related to 
treatment; two in patients treated with 20 μg/kg 
palonosetron (on-study chemotherapy cycle 2) 
and one in a patient receiving ondansetron (on-
study chemotherapy cycle 1). TEAEs with fatal 
outcome were reported in six patients during the 
reporting period; three each for patients treated 
with 20 μg/kg palonosetron (one each in on-
study chemotherapy cycles 1–3) and ondanse-
tron (two in cycle 1 and one in cycle 2). One 
additional patient in the ondansetron group died 
after the reporting period. All these deaths were 
 considered to be unrelated to study drug.
Discussion
The investigation of 5-HT
3
 receptor antago-
nists in the prevention of CINV in pediatric 
patients has mainly involved granisetron and 
ondansetron [21–23], and ondansetron is com-
monly adopted in this setting. We have previ-
ously reported noninferiority for single dose 
20 μg/kg palonosetron compared with multiple 
doses of 150 μg/kg ondansetron during the acute 
phase of the first on-study chemotherapy cycle in 
 pediatric patients receiving MEC or HEC [17].
In the present analysis, the number of patients 
with CRs was higher in the 20 μg/kg palono-
setron group across all phases and all four on-
study chemotherapy cycles compared with those 
treated in the ondansetron group. In particular, 
Mantel–Haenszel analysis of data from the sec-
ond on-study chemotherapy cycle was consistent 
with the previously reported formal demonstra-
tion of the noninferiority of 20 μg/kg palono-
setron compared with ondansetron in the acute 
phase of the first on-study chemotherapy cycle. 
The proportion of patients with no vomiting, no 
emetic episodes and with no use for antiemetic 
rescue medication across on-study chemother-
apy cycles 1–4 and during all phases was also 
higher in patients in the 20 μg/kg compared 
with the ondansetron group (except for no use 
for antiemetic rescue medication in the acute 
phases of on-study cycles 1 and 2). As previ-
ously reported for the delayed phase of cycle 
1 [17], the 95% CI calculated for the difference 
in the proportion of patients experiencing no 
emetic episodes in the 20 μg/kg palonosetron 
and ondansetron groups (Δ 15.38% [95% CI: 
5.1–25.7]) did not include a zero value, indicat-
ing that the efficacy of this dose of palonosetron 
table 3. summary of overall treatment-emergent adverse events by Medical Dictionary for Regulatory activities system Organ 
class and preferred term.
MedDRa sOc/preferred term† Palonosetron (10 μg/kg)  
n = 167
Palonosetron (20 μg/kg)  
n = 163
Ondansetron (3 × 150 μg/kg) 
n = 164
Any 143 (85.6) 130 (79.8) 145 (88.4)
Blood and lymphatic disorders 105 (62.9) 101 (62.0) 111 (67.7)
  – Anemia 77 (46.1) 70 (42.9) 73 (44.5)
  – Thrombocytopenia 43 (25.7) 38 (23.3) 43 (26.2)
  – Leucopenia 43 (25.7) 29 (17.8) 50 (30.5)
  – Neutropenia 44 (26.3) 36 (22.1) 31 (18.9)
  – Febrile neutropenia 36 (21.6) 34 (20.9) 27 (16.5)
Gastrointestinal disorders 57 (34.1) 59 (36.2) 68 (41.5)
  – Vomiting 14 (8.4) 18 (11.0) 22 (13.4)
  – Abdominal pain 17 (10.2) 13 (8.0) 18 (11.0)
  – Stomatitis 11 (6.6) 13 (8.0) 13 (7.9)
  – Diarrhea 13 (7.8) 8 (4.9) 14 (8.5)
  – Constipation 9 (5.4) 10 (6.1) 8 (4.9)
General disorders and administration site conditions 47 (28.1) 38 (23.3) 40 (24.4)
  – Pyrexia 34 (20.4) 22 (13.5) 25 (15.2)
Investigations 39 (23.4) 37 (22.7) 36 (22.0)
  – White blood cell count decreased 16 (9.6) 18 (11.0) 19 (11.6)
  – Platelet count decreased 12 (7.2) 12 (7.4) 10 (6.1)
Nervous system disorders 23 (13.8) 20 (12.3) 24 (14.6)
  – Headache 17 (10.2) 9 (5.5) 17 (10.4)
Data are number of patients (%) in the safety population.
†Listed are MedDRA SOC and preferred terms in >5% of patients in either treatment group.
MedDRA: Medical Dictionary for Regulatory Activity; SOC: System Organ Class.
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during this phase might be superior to that of 
ondansetron. Furthermore, in adult cancer 
patients, older class setron agents when used 
in recommended doses were not as efficacious 
as palonosetron in the control of delayed eme-
sis [24–26]. Controlling delayed emesis remains 
an unmet clinical need [27], and palonosetron 
might, therefore, provide much needed relief to 
pediatric cancer patients for up to 5 days fol-
lowing multicycle emetic chemotherapy, often 
following discharge from hospital.
Interpretation of the multicycle data, how-
ever, should be treated with some caution due 
to the small number of patients in some of the 
treatment groups and strata, particularly in later 
chemotherapy cycles. This was mainly due to 
the expected high rate of patients not continu-
ing with each subsequent cycle, thus analysis 
using stratum adjusted Mantel–Haenszel was 
not possible in on-study chemotherapy cycles 3 
and 4. In addition, in general in multicycle stud-
ies, the patients responding best to treatments 
tend to remain in the study for a higher number 
of cycles; this may be considered as a potential 
source of bias. The inclusion of patients sched-
uled to receive multiple day (day 1 and addi-
tional days) chemotherapy also complicates the 
interpretation of outcome in the delayed and 
table 4. summary of overall drug-related adverse events.
MedDRa sOc/preferred term Palonosetron (10 μg/kg), 
n = 167
Palonosetron (20 μg/kg), 
n = 163
Ondansetron (3 × 150 μg/
kg), n = 164
At least one 9 (5.4) 8 (4.9) 10 (6.1)
Nervous system disorders      
  – Headache 4 (2.4) 1 (0.6) 3 (1.8)
  – Dizziness 1 (0.6) 1 (0.6) 0
  – Dyskinesia 0 1 (0.6) 0
Cardiac disorders      
  – Sinus tachycardia 1 (0.6) 0 2 (1.2)
  – Conduction disorder 1 (0.6) 0 1 (0.6)
Investigations      
  – Electrocardiogram QT prolonged 0 1 (0.6) 2 (1.2)
Skin and subcutaneous disorders      
  – Dermatitis allergic 0 1 (0.6) 0
  – Skin disorder 0 1 (0.6) 0
  – Urticaria 0 0 1 (0.6)
General disorders and administration site conditions      
  – Infusion site erythema 1 (0.6) 0 0
  – Infusion site pain 0 1 (0.6) 0
  – Infusion site reaction 1 (0.6) 0 0
Musculoskeletal and connective tissue disorders      
  – Muscle spasms 0 0 1 (0.6)
  – Musculoskeletal pain 0 0 1 (0.6)
Respiratory, thoracic and mediastinal disorders      
  – Cough 1 (0.6) 0 0
  – Dyspnea 1 (0.6) 0 0
  – Epistaxis 1 (0.6) 0 0
Blood and lymphatic system disorders      
  – Thrombocytopenia 1 (0.6) 0 0
Gastrointestinal disorders      
  – Diarrhea 0 1 (0.6) 0
Metabolism and nutrition disorders      
  – Dehydration 0 1 (0.6) 0
Vascular disorders      
  – Hypertension 0 0 1 (0.6)
Data are number of patients (%) in the safety population.
MedDRA: Medical Dictionary for Regulatory Activity; SOC: System Organ Class.
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overall phases. However, given that many pedi-
atric chemotherapy regimens are multiple day, 
this was deemed to be necessary at the time of 
study design to ensure that sufficient patients 
could be enrolled to allow for the evaluation 
of efficacy. The chosen model of randomiza-
tion and double blinding minimizes the impact 
of this limitation when comparing treatment 
groups. A further limitation is that the assess-
ment of the efficacy during the delayed phase of 
cycles 2–4 was based on questions to the patient 
120 h after the start of the chemotherapy, so 
the patient had to remember if she or he had 
experienced vomiting/retching/nausea over the 
last 4 days. Because the assessment of vomiting 
and retching was performed differently in cycles 
2–4 compared with cycle 1, the efficacy should 
be analyzed by cycle comparing the treatment 
groups. The comparison of treatment between 
cycle 1 and the other cycles could be subject to 
recall bias issues.
The safety profile across all four chemother-
apy cycles was as to be expected for patients 
receiving MEC and HEC. The most commonly 
reported TEAEs over four cycles of chemother-
apy included MedDRA preferred terms listed 
under the SOC blood and lymphatic disorders, 
gastrointestinal disorders and general disorders 
and administration site conditions. Progression 
into subsequent on-study chemotherapy cycles 
did not appear to induce worsening of TEAEs 
in any SOC. No clinically relevant differences 
were reported between patients treated with 10 
or 20 μg/kg palonosetron (with no incremen-
tal toxicity evident) or ondansetron. However, 
we note that fewer patients receiving 20 μg/kg 
palonosetron had grade ≥3 TEAEs in on-study 
chemotherapy cycles 1–4 than those in the 
10 μg/kg palonosetron and ondansetron groups. 
The overall frequency of TEAEs considered to 
be related to treatment was low in the palono-
setron 10 μg/kg (9 [(5.4%] of 167 patients), 
20 μg/kg (8 [4.9%] of 163 patients) and ondan-
setron (10 [6.1%] of 164 patients) groups, and 
all were reported during on-study chemotherapy 
cycles 1 and 2. Nervous system disorders (head-
ache, dizziness and dyskinesia) were the most 
commonly reported adverse events related to 
treatment. Older class 5-HT
3
 receptor antag-
onists are reportedly associated with a risk of 
inducing adverse cardiac events (electrocardio-
gram changes and arrhythmias), although stud-
ies suggest palonosetron to be less of a risk for 
these events [10,28,29]. In total, treatment-related 
cardiac disorders were reported in one patient 
receiving 10 μg/kg palonosetron and two receiv-
ing ondansetron. Treatment-related prolonged 
electrocardiogram QT was reported in one 
patient receiving 20 μg/kg palonosetron and 
two treated with ondansetron. Discontinuations 
associated with TEAEs, and TEAEs with a fatal 
outcome were not considered to be treatment 
related.
conclusion
This pivotal study demonstrated 20 μg/kg palo-
nosetron to be noninferior to 3 × 150 μg/kg 
ondansetron in the prevention of CINV during 
the acute phase of the first on-study chemother-
apy cycle in pediatric cancer patients (aged 0 to 
<17 years) receiving HEC or MEC. The data 
reported here show that over all four treatment 
cycles of HEC or MEC, 20 μg/kg palonose-
tron appeared to be an efficacious treatment for 
the prevention of CINV in these patients. The 
safety profile was consistent with those previ-
ously reported for palonosetron and ondansetron 
and did not indicate a risk to pediatric patients 
treated in this setting.
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summary points
 ●  Palonosetron is a comparatively new 5-hydroxytryptamine-3 receptor antagonist with a higher affinity for the 
5-hydroxytryptamine-3 receptor and a longer plasma elimination half-life than older agents of this class.
 ●  This pivotal randomized Phase III double-blind, double-dummy noninferiority study in 493 pediatric cancer patients 
treated with highly or moderately emetogenic chemotherapy (HEC/MEC) showed that palonosetron (20 μg/kg) was 
noninferior to ondansetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the acute 
phase (0–24 h) of the first on-study chemotherapy cycle.
 ●  In the current analyses, we explored the efficacy and safety of two dose levels of palonosetron (10 and 20 μg/kg) 
versus ondansetron in relation to the prevention of CINV in each of the four chemotherapy cycles of this study.
 ●  Complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group in 
all phases of all on-study chemotherapy cycles.
 ●  Efficacy was also generally higher in the 20 μg/kg palonosetron group for no vomiting, absence of emetic episodes, 
avoidance of antiemetic rescue medication and no nausea.
 ●  Controlling emesis remains an unmet medical need and palonosetron may, therefore, provide much needed relief to 
pediatric patients for up to 5 days following multicycle HEC/MEC.
 ●  The overall incidence of treatment-emergent adverse events (TEAEs) was comparable between the palonosetron and 
ondansetron groups, with the safety profile of palonosetron consistent with previous reports.
 ●  Discontinuations associated with TEAEs and TEAEs with a fatal outcome were not considered to be treatment related.
 ●  In summary, our data show that over four cycles of HEC/MEC, 20 μg/kg palonosetron is an efficacious and safe 
treatment for the prevention of CINV in pediatric cancer patients aged 0 to <17 years.
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